AMLX: the balance sheet

MyFinsight

Amylyx Pharmaceuticals, Inc. (AMLX)

Balance Sheets	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Cash and cash equivalents	229,136	226,651	225,178	58,085
Marketable securities	50,632	90,328	118,812	122,741
Accounts receivable, net	NaN	88	132	103
Prepaid expenses and other current assets	5,256	6,604	9,261	5,961
Total current assets	285,024	323,671	353,383	186,890
Total property and equipment	NaN	1,864	NaN	NaN
Less accumulated depreciation	NaN	1,554	NaN	NaN
Property and equipment, net	212	310	399	445
Restricted cash equivalents	986	985	983	1,451
Operating lease right-of-use assets	4,881	5,181	5,476	5,812
Deposits and other assets	NaN	2,498	NaN	NaN
Other assets	2,500	NaN	2,500	NaN
Total assets	293,603	332,645	362,741	194,598

Accounts payable	3,529	3,519	5,339	3,294
Accrued expenses	11,282	17,910	19,471	17,465
Operating lease liabilities, current portion	1,155	1,259	981	665
Total current liabilities	15,966	22,688	25,791	21,424
Operating lease liabilities, net of current portion	4,476	4,698	4,954	5,297
Total liabilities	20,442	27,386	30,745	26,721
Common stock, 0.0001 par value 300,000,000 shares authorized 111,026,477 and 109,884,502 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively	11	11	11	9
Additional paid-in capital	1,065,621	1,056,271	1,049,598	851,359
Accumulated deficit	-792,711	-751,427	-718,428	-684,042
Accumulated other comprehensive income	240	404	815	551
Total stockholders' equity	273,161	305,259	331,996	167,877
Total liabilities and stockholders' equity	293,603	332,645	362,741	194,598

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.